DocDollars

Novartis Pharmaceuticals Corporation

NJ · United States · Reporting entity ID 100000000228

Total reported 2019–2025
$3.55B
#4 of 2,960 reporting companies — 4.3% of all reported industry payments
$144.5M in general payments across 2,338,963 records, plus $3.41B in research funding across 50,689 records.

How it breaks down

General payments $144,466,766
Research funding $3,405,749,898

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Novartis Pharmaceuticals Corporation reported $3.55B to US doctors and teaching hospitals from 2019 to 2025, ranking #4 of 2,960 reporting companies. 96% of that was research funding and 4% general payments such as consulting, speaking, food and travel. 2,338,963 general payment records and 50,689 research records were filed.

Common questions about Novartis Pharmaceuticals Corporation

How much has Novartis Pharmaceuticals Corporation paid US doctors?

Novartis Pharmaceuticals Corporation reported $3,550,216,664 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $144,466,766 in general payments, $3,405,749,898 in research funding.

How does Novartis Pharmaceuticals Corporation rank among drug and device companies?

It ranks #4 of 2,960 reporting entities by total reported value, about 4.3% of all industry payments in the dataset.

Does a payment from Novartis Pharmaceuticals Corporation mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.